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Blueberries Improve Glucose Tolerance Without Altering
Body Composition in Obese Postmenopausal Mice
Carrie M. Elks1, Jennifer D. Terrebonne2, Donald K. Ingram3, and Jacqueline M. Stephens1
Objective: Metabolic syndrome (MetS) risk increases significantly during menopause and remains ele-
vated postmenopause. Several botanicals, including blueberries (BB), have been shown to delay MetS
progression, but few studies have been conducted in postmenopausal animal models. Here, the effects
of BB supplementation on obese postmenopausal mice using a chemically induced menopause model
were examined.
Methods: After induction of menopause, mice were fed a high-fat diet or the same diet supplemented
with 4% BB powder for 12 weeks. Body weight and body composition were measured, and mice were
subjected to glucose and insulin tolerance tests. Serum triglycerides and adiponectin were measured,
and liver histology and hepatic gene expression were assessed.
Results: Menopausal and BB-supplemented mice had significantly higher body weights and fat mass
than control mice, while menopausal mice had impaired glucose tolerance and higher serum triglycerides
when compared with control and BB-supplemented mice. Menopausal mice also had hepatic steatosis
that was prevented by BB supplementation and correlated with expression of genes involved in hepatic
fatty acid oxidation.
Conclusions: BB supplementation prevents the glucose intolerance and hepatic steatosis that occur in
obese postmenopausal mice, and these effects are independent of body weight.
Obesity (2015) 23, 573–580. doi:10.1002/oby.20926
Introduction
Menopause, the permanent cessation of menstruation and fertility,
occurs in American women at a mean age of 51 years (1). Approxi-
mately, 49 million women in the US are currently considered post-
menopausal. Metabolic syndrome (MetS) affects 40% of people over
age 60 and is a significant risk factor for the development of type 2
diabetes (1). Women of reproductive age are considered to be at
lower risk for MetS in comparison to men of similar age; however,
MetS risk increases significantly during the perimenopausal period
and remains elevated postmenopause (2). The estrogen decline
observed during menopause was once thought to increase MetS risk;
however, it is now known that a progressive increase in the
“androgenicity” of the hormonal milieu is the primary culprit, not
estrogen loss per se (2,3).
The most common animal model for menopause research is ovariec-
tomy, where the ovaries are removed surgically. More recently, a
menopausal mouse model with intact ovaries was developed using 4-
vinylcyclohexene diepoxide (VCD), an occupational chemical that
accelerates the natural process of follicular atresia (4-6). With this
model, repeated daily dosing allows the gradual onset of ovarian fail-
ure while the residual ovarian tissue remains intact (4-6). Similar to
humans, the residual ovarian tissue of VCD-injected mice produces
androgens, which contribute to the altered estrogen/androgen ratio
thought to increase MetS risk. For these reasons, the VCD model is
more representative of the natural progression of menopause (4-6).
Notably, there has been a recent shift of research and public interest
toward the potential of whole foods to mitigate a variety of health
conditions, including MetS. Several botanicals have been shown to
delay MetS progression, but these types of studies are lacking in
postmenopausal animals. One whole food that has been shown to
attenuate obesity, dyslipidemia, and/or insulin resistance in several
preclinical models of MetS is the blueberry (BB; Vaccinium species)
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(7-10), which therefore may be a feasible option for the natural
treatment of this disorder.
The purpose of this study was to assess the effects of BB supplemen-
tation in high-fat diet-fed postmenopausal mice. We examined param-
eters associated with MetS in cycling control, menopausal, and BB-
supplemented menopausal mice fed a high-fat diet for 12 weeks.
Measured parameters included: weight gain, body composition, fast-
ing blood glucose levels, glucose and insulin tolerance, serum triglyc-
erides, and hepatic steatosis. Our results demonstrate that ovarian fail-
ure/menopause, in combination with a high-fat diet, in the C57BL/6J
mouse leads to obesity, glucose intolerance, and hepatic steatosis, and
that BB-supplementation prevents the development of the glucose
intolerance and hepatic steatosis in this animal model.
Methods
Animals and diets
Four-week old female C57BL/6J mice were purchased from Jackson
Laboratories (Bar Harbor, ME). Animals were housed in a tempera-
ture (22C 6 2C)- and humidity-controlled (45-55%) room under a
12-h light/dark cycle (lights on from 0700 h-1900 h). All animals
were housed in groups of 3-4 for the duration of the study. Mice
were allowed ad libitum access to food and water, and body weights
were measured weekly. All experiments were approved by the Pen-
nington Biomedical Research Center Institutional Animal Care and
Use Committee. Three groups of mice were used in this study.
Groups were: high-fat diet (HFD) cycling (C; n 5 4), HFD1VCD
injections (V; n 5 6), HFD1BB1VCD (VB; n 5 8).
A complete study timeline appears in Table 1. Briefly, immediately
upon arrival to the animal facility, mice were placed on a purified
low-fat pelleted control diet (D12450J; Research Diets, New Bruns-
wick, NJ). Two days after VCD injections were completed, all ani-
mals were switched to a purified high-fat pelleted diet (HFD,
D12429; Research Diets, New Brunswick, NJ). All animals were
maintained on HFD until confirmation of menopause (60 days fol-
lowing the first VCD injection; study week 8). Once menopause
was confirmed, animals in the VB group were switched to the same
pelleted HFD with 4% wt:wt highbush BB powder (batch T-10711)
from the Tifblue (Vaccinium virgatum (ashei)) cultivar added; the
BB was incorporated into the HFD by Research Diets as a custom
formulation. Diets were isocaloric at 5.1 kcal/g and each contained
18% kcal from protein, 21% kcal from carbohydrate, and 61% kcal
from fat. The BB powder was a kind gift from the United States
Highbush Blueberry Council. Mice were maintained on their respec-
tive diets for 12 additional weeks. Fresh diet was provided every
other day to minimize fat oxidation and deterioration of BB active
ingredients, and diet was stored at 280C until use. Diet composi-
tions are indicated in Table 2, and the nutrient composition of the
BB powder used appears in Table 3.
Induction of menopause
After a 1-week acclimation to the animal room, 5-week old mice were
weighed and injected intraperitoneally (i.p.) each day with VCD, at a
concentration of 160 mg/kg for 17 consecutive days; this dosing regi-
men has been optimized by the creators of the VCD menopause model
(5,11). Control mice were injected daily with sesame oil vehicle. After
completion of injections, vaginal cytology was monitored daily to
assess estrous cycle cessation. Briefly, vaginal lavage was performed
on each mouse (between 7 a.m. and 9 a.m. daily) using 20 ul of sterile
0.9% saline. A drop of fluid from each lavage was placed onto a slide,
allowed to air dry, stained with 0.25% methylene blue, and viewed
under a microscope to determine cycle stage. Mice were considered
acyclic after 10 days of consecutive diestrus (5,11). After mice were
sacrificed, ovaries were removed, and periovarian fat was trimmed
away and stored for later analysis. A piece of liver from each animal
was removed and frozen at 280C for later analysis. Another piece of
liver from each animal was formalin-fixed, paraffin-embedded, and
sectioned at a thickness of 3 um; sections were placed on slides and
stained with hematoxylin and eosin for histologic evaluation.
Body composition measurements and blood
collection
Non-fasting body composition was analyzed by NMR (Bruker LF50,
Bruker Optics, Germany) at baseline and every other week on all
mice for the duration of the study. Body weights were obtained
weekly. At baseline and study end, mice were fasted for 4 h, and
tail blood glucose was measured using a Bayer Breeze 2 glucometer.
At baseline and study end, submandibular venous blood was col-
lected from fasted mice (4 h). Mice were anesthetized with
TABLE 1 Study timeline
Week 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
Randomization 
Injections (17 days)  
High-fat diet     
Vaginal cytology      
High-fat diet 2/1 BB            
Food intake &
body weight                     
Body composition           
GTT 
ITT 
Abbreviations used: BB, blueberry; GTT, glucose tolerance test; ITT, insulin tolerance test.
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isoflurane, and the submandibular vein punctured with a sterile lan-
cet. Several drops of blood were collected into sterile serum separa-
tor tubes. Blood was centrifuged at 3,500 rpm for 15 min at 4C,
and serum was removed and stored at 280C.
Insulin and glucose tolerance testing
Insulin tolerance tests and glucose tolerance tests (ITT and GTT,
respectively) were performed on mice after a 4-h light phase fast (8
a.m. to noon, for ITT) or a 12-h overnight fast (8 p.m. to 8 a.m., for
GTT). ITT was performed at noon 2 weeks prior to sacrifice and
GTT was performed at 8 a.m. 1 week prior to sacrifice. Tail glucose
was measured at baseline (time 0) prior to the administration of
insulin or glucose. I.p. injections of insulin (0.8 mU/g body weight,
Sigma Aldrich, USA) or D-glucose (1.6 mg/g body weight, Fisher
Scientific, USA) were given, and tail glucose measured at 20, 45,
60, 90, and 120 min postinjection.
Gene expression analyses
Total RNA from 100 mg of tissue was isolated by column purifica-
tion (Qiagen) and yield determined by spectrophotometry (NanoDrop
Technologies). From each RNA sample, 200 ng was reverse tran-
scribed to cDNA using the High Capacity cDNA Reverse Transcrip-
tion kit (Applied Biosystems). Relative quantification of mRNA
expression was analyzed using an ABI Prism 7900 Sequence Detection
System (Applied Biosystems). PPIA was used as a “housekeeping”
control gene. Mouse primers came from Integrated DNA Technolo-
gies, and the sequences were as follows: PPIA (cyclophilin A) for-
ward, CACTGTCGCTTTTCGCCGC; PPIA (cyclophilin A) reverse,
TGCAAACAGCTCGAAGGAGACGC; Cs (citrate synthase) forward,
GTCCATGCAGTCCTCATAGATG; Cs (citrate synthase) reverse,
CTCAACAGTGAAAGCAACTTCG; Hadha (long-chain hydroxyacyl-
CoA dehydrogenase) forward, GCTATTCTGTATTGGCATGCTATG;
Hadha (long-chain hydroxyacyl-CoA dehydrogenase) reverse, CGACT
CTCACAGGAAGGTCAGAG; Cd36 (fatty acid translocase) forward,
GGCATCATTGGGCACTCCTT; Cd36 (fatty acid translocase)
reverse, ACCAACAGCTGCCATGGATC.
Serum and tissue analyses
Serum triglycerides and serum adiponectin were assayed using kits
from Sigma (St. Louis, MO) and Millipore (Billerica, MA), respec-
tively, according to manufacturer’s instructions. Quantification of
liver triglycerides was performed using a kit from Abcam (Cam-
bridge, MA) according to manufacturer’s instructions.
Statistical analyses
For results over time, repeated measures ANOVA was performed.
Student’s t-tests were performed on NMR, GTT area under the
curve, liver triglycerides, and serum triglycerides. Analysis of covar-
iance (ANCOVA) was performed on serum adiponectin values with
group and fat mass as covariants. Differences in results were consid-
ered significant when P< 0.05.
Results
Body weight and body composition
Body weights of postmenopausal (V) or postmenopausal with BB
supplementation (VB) mice were significantly greater than those of
control (C) mice beginning at study week 6 and continuing through
study end (Figure 1A). Both groups of menopausal mice had signifi-
cantly greater fat mass, but no changes in fat free mass, compared
with control mice (Figure 1B). There were no differences in body
weight, fat mass, or fat free mass between the V and VB groups,












Soybean oil 25 25
Lard 245 245
Mineral mix 10 10
DiCalcium phosphate 13 13
Calcium carbonate 5.5 5.5
Potassium citrate 16.5 16.5
Vitamin mix 10 10
Choline bitartrate 2 2
Blueberry powder 0 31.2
Ingredients are presented as grams per kilogram of diet.






Saturated fat (g) 0.16






Dietary fiber (g) 24.0
Insoluble fiber (g) 20.9
Soluble fiber (g) 3.1
Cholesterol (mg) 0
Total beta carotene (IU) 0





Abbreviations used: g, grams; kcal, kilocalories; IU, international units; mg,
milligrams.
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indicating that BB supplementation did not affect these parameters.
In support of these data, cumulative food intake estimates per cage
over study weeks 8-20 did not differ between the V and VB groups,
although both groups consumed more than the C group (data not
shown).
Blood glucose measurements
Compared to VB mice, mice in the V group had significantly higher
blood glucose levels after a 4-h fast (P 5 0.0259). There were no
significant differences among blood glucose levels at any other time
points during an ITT (Figure 2A). In contrast with the ITT results,
both the C and VB groups had significantly lower blood glucose
levels than V mice for most time points throughout a GTT (Figure
2B) and significantly lower GTT area under the curve values (Figure
2C), suggesting that BB supplementation may prevent the develop-
ment of glucose intolerance in obese postmenopausal mice.
Serum measurements
Serum triglycerides were significantly higher in obese postmeno-
pausal mice when compared to C and VB mice (Figure 3A). Inter-
estingly, serum adiponectin was higher in both the V and VB mice
than in the control mice, although these differences were not signifi-
cant. However, the increased fat mass may account for the increased
adiponectin production observed in both groups of menopausal ani-
mals (Figure 3B). When ANCOVA was performed using group and
fat mass as covariants, fat mass was found to have a significant
effect on serum adiponectin (P 5 0.0094).
Liver histology, triglyceride content, and gene
expression
As expected with the HFD, some lipid deposition was observed in
livers from animals in all groups, but was much more severe in V
mice than in control mice (Figure 4A-C). Livers from VB mice had
less hepatic steatosis than livers from V mice, indicating that BB
supplementation may prevent the increased lipid deposition present
in the livers of obese postmenopausal mice. Results from the liver
triglyceride quantification assay supported our histology results, with
significantly higher liver triglyceride levels in the V group when
compared to the C and VB groups (Figure 4D). In addition, hepatic
gene expression analyses revealed significant increases in citrate
synthase, long-chain hydroxyacyl-CoA dehydrogenase, and fatty
acid translocase/CD36 in VB animals when compared to V animals,
suggesting enhanced fatty acid oxidation in the livers of BB-treated
obese postmenopausal mice (Figure 5A-C).
Discussion
The purpose of this study was to assess the effects of BB supple-
mentation on body composition, glucose tolerance, and lipid han-
dling in obese postmenopausal mice. We used the VCD injection
model of ovarian failure that causes gradual follicle loss and allows
for retention of residual ovarian tissue that produces androgens that
may contribute to postmenopausal metabolic dysfunction (4,5).
Here, we combined the VCD menopause model with a 60% high-fat
diet to induce obesity. MetS studies are generally conducted in high-
fat-fed male C57BL/6J mice since they gain more weight, are
obesity-prone, and become insulin-resistant (12,13), while high-fat
diet-fed female mice of reproductive age do not tend to become
insulin-resistant (13). Very few studies have examined the effects of
high-fat diet feeding in postmenopausal C57BL/6J mice, and our
study is the first to examine the effects of BB supplementation in
these mice. Our data demonstrate that high-fat diet-fed VCD-
injected mice become obese and glucose intolerant and develop
hepatic steatosis, and that BB supplementation can prevent the glu-
cose intolerance and hepatic steatosis observed in these animals.
Menopause is associated with gains in body weight and fat mass in
both humans and animals (4,14-19). In line with previous results in
VCD-injected B6C3F1 mice (4) and ovariectomized mice (15,18,19),
our menopausal animals had significantly greater body weights and
fat mass than cycling control animals; interestingly, BB supplemen-
tation did not significantly affect either parameter. Previous studies
in ovariectomized female rats have also demonstrated no differences
in body weights between control- or BB-fed groups, although the
diets used were not high-fat (20,21). Also, no changes in fat mass or
Figure 1 Menopause-induced changes in body weight and body composition are not altered by BB supplementation. (A) Body
weights for all animals throughout study duration. Body weights of VCD-injected mice and BB-supplemented VCD-injected mice
were not significantly different from each other but were significantly different from those of control mice from weeks 8-20 of the
study. (B) Mean body composition data for various groups at study end (20 weeks). Control mice had significantly less fat mass
than V or VB mice, but no changes in fat free mass or fluid were noted. *P<0.05, **P< 0.01, C group vs. other two groups.
HFD 5 high-fat diet, BB 5 blueberry, C 5 cycling HFD control group, V 5 HFD1VCD, VB 5 HFD1BB1VCD, g 5 grams. [Color
figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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body weight were reported in BB-supplemented high-fat-fed male
mice (9,22) or obese male Zucker rats (8). These results are sup-
ported by the lack of any substantial changes in food intake between
the menopausal and BB-supplemented menopausal mice in our study
(data not shown). Conversely, increases in energy intake, fat mass,
and body weight have been reported in male rodents with BB sup-
plementation. The study reporting increased energy intake in HFD-
fed male mice provided 10% BB, which is 250% more BB than we
Figure 3 BB supplementation improves serum triglycerides in obese postmenopausal mice. (A) Serum triglyceride lev-
els at study end. (B) Serum adiponectin levels at study end. *P<0.05 vs. V group. C 5 cycling HFD control group,
V 5 HFD1VCD, VB 5 HFD1BB1VCD, mg 5 milligrams, dl 5 deciliter, ug 5 micrograms, ml 5 milliliter. [Color figure can
be viewed in the online issue, which is available at wileyonlinelibrary.com.]
Figure 2 BB supplementation does not improve insulin tolerance, but does improve glucose tolerance, in obese post-
menopausal mice. (A) Graphical depiction of insulin tolerance time following an i.p. insulin injection. At baseline, V
mice had higher blood glucose levels than VB or C groups; however, no changes in blood glucose levels over time
were noted among any of the groups in response to an insulin injection. (B) Graphical depiction of glucose tolerance
over time following an i.p. bolus of glucose. V mice demonstrated impaired glucose tolerance at 30, 45, 60, and 90
min postinjection. (C) GTT results expressed as area under the curve *P< 0.05, **P< 0.01 vs. V group. C 5 cycling
HFD control group, V 5 HFD1VCD, VB 5 HFD1BB1VCD, mg 5 milligrams, dl 5 deciliter, A.U. 5 arbitrary units. [Color
figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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Figure 4 BB supplementation prevents hepatic steatosis in obese postmenopausal mice. Representative photomicrographs of H&E-
stained liver sections at 1003 magnifications. Scale bars 5 50 mm. The livers of (B) V mice had more severe lipid deposition than (A) C
mice, and BB supplementation prevented the lipid deposition seen in (C) the menopausal liver. (D) These qualitative histologic results
were verified with a quantitative method for tissue triglyceride measurement. * P< 0.05 vs. V group. C 5 cycling HFD control group,
V 5 HFD1VCD, VB 5 HFD1BB1VCD, mg 5 milligrams, g 5 grams.
Figure 5 Menopause decreases expression of genes associated with hepatic fatty acid oxidation, and BB supple-
mentation prevents these changes. Relative expression levels of hepatic (A) CD36, (B) Cs, and (C) Hadha in livers
after 12 weeks of HFD or HFD supplemented with BB. **P< 0.01, ****P<0.0001 vs. V group. C 5 cycling HFD con-
trol group, V 5 HFD1VCD, VB 5 HFD1BB1VCD, Cd36 5 fatty acid translocase/CD36, Cs 5 citrate synthase, and
Hadha 5 long-chain hydroxyacyl-CoA dehydrogenase.
Obesity Blueberries and Postmenopausal Obesity Elks et al.
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provided (10). In this study, the increased levels of BB may have
increased diet palatability, as BB-supplemented animals consumed
12% more energy per day; this could have led to increased body
fat. In the aforementioned Zucker rat study, an increase in body
weight, but not adiposity, was only observed in the low-fat-fed lean
control Zucker rats with 2% BB supplementation, and not in the
high-fat-fed obese Zucker rats (8). Nonetheless, our current results
suggest that the metabolically beneficial effects of BB supplementa-
tion in obese postmenopausal mice are independent of alterations in
body weight and body composition.
Estrogen is known to improve glucose homeostasis in mice and
humans (23-27). The elevated blood glucose levels and impaired glu-
cose tolerance seen in our obese postmenopausal mice support previ-
ous results demonstrating the effects of menopause/estrogen loss on
glucose homeostasis in vivo (4,15,18,23,27-30). In VCD-injected
B6C3F1 mice, significantly higher blood glucose levels after a 4-h
fast and impaired glucose tolerance were observed after 16 weeks on
a high-fat diet (4). Similar effects have been shown in ovariectomized
high-fat diet-fed mice (15,28-30). Our BB-supplemented postmeno-
pausal mice had significantly lower blood glucose levels after a 4-h
fast and improved glucose tolerance when compared to non-
supplemented menopausal mice. These results demonstrate metabol-
ically favorable, weight-independent effects of BB on glucose metab-
olism in the postmenopausal state. Interestingly, although 4-h fasting
blood glucose was elevated in menopausal mice compared to BB-
supplemented menopausal mice, there were no differences in blood
glucose after a 12-h fast. Our results suggest that liver may contribute
to this effect. If the menopausal mice had hepatic insulin resistance,
the mild 4-h fast could result in increased hepatic glucose output in
excess of the glucose demands of other tissues, thereby leading to ele-
vated blood glucose. However, the severity of the 12-h fast would
likely have led to an increase in tissue demand for glucose to match
hepatic glucose output, and would have likely led to a normalization
of glucose levels as we observed in our study. Overall, additional
studies utilizing hyperinsulinemic-euglycemic clamping are required
to provide more detailed information regarding the tissues responsible
for the improved glucose tolerance in these animals.
Alterations in lipid homeostasis are common in menopausal female
rodents and humans; specifically, increased cholesterol, triglycerides, and
free fatty acids are often present (3,4,27,31). Hepatic steatosis is also a
common feature in menopausal animal models (27,31,32). As expected,
compared to control mice, our postmenopausal mice had increased serum
triglycerides and hepatic steatosis, while BB supplementation prevented
these effects. Supplementation of high-fat diet with BB or its active com-
ponents has been previously shown to mitigate the changes in lipid levels
seen in several male rodent models of MetS (22,33-35), but until now, no
studies have examined BB effects on serum lipids or hepatic steatosis in
obese postmenopausal mice. Our results support previous findings regard-
ing circulating and hepatic lipid levels in BB-supplemented rodents but
now extended these findings to females.
One possible explanation for the prevention of hepatic steatosis in the
BB-supplemented mice is an enhancement in hepatic fatty acid oxida-
tion. In liver, menopause/estrogen loss is associated with a decrease in
the partitioning of triglyceride into oxidative pathways (36). Consistent
with this observation, expression levels of key hepatic fatty oxidation
genes (citrate synthase, long-chain hydroxyacyl-CoA dehydrogenase,
and fatty acid translocase/CD36) were decreased in our menopausal
mice when compared to controls. Expression levels of all three genes
in BB-supplemented mice were similar to control levels, suggesting an
improvement in hepatic fatty acid oxidation and lipid handling, which
may explain the vast improvements in liver histology and the decrease
in serum triglycerides seen in these animals. Decreased hepatic citrate
synthase, which indicates an overall decline in total mitochondrial oxi-
dative capacity, has been demonstrated with high-fat diet feeding in
male mice (37), but no evidence exists in female mice. Our results are
the first to demonstrate the beneficial effects of BB supplementation
on hepatic fatty acid oxidation and hepatic lipid deposition in the post-
menopausal mouse liver. In addition to its possible effects on hepatic
steatosis, the improvement in hepatic fatty acid oxidative gene expres-
sion also suggests a route by which glucose tolerance may be
improved in our BB-supplemented mice.
Although our data in liver are compelling, it is worth noting that some
of the beneficial effects of BB supplementation we observed in this
study may not be directly due to liver effects, but instead due to
improved adipose tissue function. It is well-accepted that in obesity and
insulin resistance, adipose tissue lipolysis provides fatty acids that con-
tribute to hepatic triglyceride deposition and development of hepatic
steatosis (38). Thus, if insulin resistance was prevented in the BB-
supplemented animals, an increase in adipose lipolytic rate may have
been avoided, allowing for improved triglyceride sequestration and
decreased ectopic lipid deposition, which would have also decreased
hepatic steatosis and improved glucose tolerance in these animals.
More detailed studies are warranted in order to test these hypotheses.
Overall, our results highlight the metabolically beneficial roles of BB
supplementation in VCD-injected C57BL/6J mice fed a high-fat diet.
After 12 weeks on the BB-supplemented diet, postmenopausal mice
exhibited no alterations in body weight or fat mass compared to their
non-supplemented counterparts, but were more glucose tolerant, had
lower serum triglycerides, and had less hepatic steatosis paired with
increased expression of key hepatic fatty acid oxidation genes. Ours is
the first study to demonstrate these effects in a postmenopausal mouse
model. These results highlight the potential utility of a natural product
in preventing the metabolic derangements observed with menopause.
It will be important to determine whether BB supplementation can
convey the same benefits in a natural menopause rodent model, or if
the benefits conferred are unique to young animals in which meno-
pause has been chemically- or surgically induced. Further investiga-
tions will be required to determine the molecular mechanisms by
which BB exert these positive effects.O
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